http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 29 Jun 2026 08:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Enveric+Biosciences+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26702308.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.enveric.com&amp;esheet=54561231&amp;newsitemid=20260629700344&amp;lan=en-US&amp;anchor=Enveric+Biosciences&amp;index=1&amp;md5=7a69c7ca817d48d6a9aedab8d0cc4e94" shape="rect">Enveric Biosciences</a> (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced its participation in the B. Riley Securities Mind, Muscle &amp; Vision Summit, being held on July 16, 2026, in Boston, MA. Joseph Tucker, Ph.D., CEO of Enveric, will participate in a Neuropsychiatry Fireside Chat to discuss current trends within the neuropsychiatry sector and the outlook for mental health drug development. </p><p> <b>Event Details:</b> </p><table cellspacing="0" class="bwtablemarginb bwblockalignl bwwidth100"> <tr> <td class="bwvertalignt bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwwidth18 bwpadl1" rowspan="1" colspan="1"><p class="bwcellpmargin"> <b>Event:</b> </p> </td> <td class="bwvertalignt http://www.streetinsider.com/Press+Releases/Enveric+Biosciences+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26702308.html Mon, 29 Jun 2026 08:00:00 -0400 A.50202486 ENVB O.05138206 O.53171475 http://www.streetinsider.com/Press+Releases/Enveric+Biosciences+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26702308.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.enveric.com&amp;esheet=54561231&amp;newsitemid=20260629700344&amp;lan=en-US&amp;anchor=Enveric+Biosciences&amp;index=1&amp;md5=7a69c7ca817d48d6a9aedab8d0cc4e94" shape="rect">Enveric Biosciences</a> (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced its participation in the B. Riley Securities Mind, Muscle &amp; Vision Summit, being held on July 16, 2026, in Boston, MA. Joseph Tucker, Ph.D., CEO of Enveric, will participate in a Neuropsychiatry Fireside Chat to discuss current trends within the neuropsychiatry sector and the outlook for mental health drug development. </p><p> <b>Event Details:</b> </p><table cellspacing="0" class="bwtablemarginb bwblockalignl bwwidth100"> <tr> <td class="bwvertalignt bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwwidth18 bwpadl1" rowspan="1" colspan="1"><p class="bwcellpmargin"> <b>Event:</b> </p> </td> <td class="bwvertalignt http://www.streetinsider.com/Press+Releases/Enveric+Biosciences+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26702308.html Mon, 29 Jun 2026 08:00:00 -0400 A.50202486 ENVB O.05138206 O.53171475 http://www.streetinsider.com/Press+Releases/Enveric+Biosciences+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26702308.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.enveric.com&amp;esheet=54561231&amp;newsitemid=20260629700344&amp;lan=en-US&amp;anchor=Enveric+Biosciences&amp;index=1&amp;md5=7a69c7ca817d48d6a9aedab8d0cc4e94" shape="rect">Enveric Biosciences</a> (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced its participation in the B. Riley Securities Mind, Muscle &amp; Vision Summit, being held on July 16, 2026, in Boston, MA. Joseph Tucker, Ph.D., CEO of Enveric, will participate in a Neuropsychiatry Fireside Chat to discuss current trends within the neuropsychiatry sector and the outlook for mental health drug development. </p><p> <b>Event Details:</b> </p><table cellspacing="0" class="bwtablemarginb bwblockalignl bwwidth100"> <tr> <td class="bwvertalignt bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwwidth18 bwpadl1" rowspan="1" colspan="1"><p class="bwcellpmargin"> <b>Event:</b> </p> </td> <td class="bwvertalignt http://www.streetinsider.com/Press+Releases/Enveric+Biosciences+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26702308.html Mon, 29 Jun 2026 08:00:00 -0400 A.50202486 ENVB O.05138206 O.53171475 http://www.streetinsider.com/Press+Releases/Enveric+Biosciences+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26702308.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.enveric.com&amp;esheet=54561231&amp;newsitemid=20260629700344&amp;lan=en-US&amp;anchor=Enveric+Biosciences&amp;index=1&amp;md5=7a69c7ca817d48d6a9aedab8d0cc4e94" shape="rect">Enveric Biosciences</a> (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced its participation in the B. Riley Securities Mind, Muscle &amp; Vision Summit, being held on July 16, 2026, in Boston, MA. Joseph Tucker, Ph.D., CEO of Enveric, will participate in a Neuropsychiatry Fireside Chat to discuss current trends within the neuropsychiatry sector and the outlook for mental health drug development. </p><p> <b>Event Details:</b> </p><table cellspacing="0" class="bwtablemarginb bwblockalignl bwwidth100"> <tr> <td class="bwvertalignt bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwwidth18 bwpadl1" rowspan="1" colspan="1"><p class="bwcellpmargin"> <b>Event:</b> </p> </td> <td class="bwvertalignt http://www.streetinsider.com/Press+Releases/Enveric+Biosciences+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26702308.html Mon, 29 Jun 2026 08:00:00 -0400 A.50202486 ENVB O.05138206 O.53171475 http://www.streetinsider.com/Business+Wire/Enveric+Biosciences+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26702308.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.enveric.com&amp;esheet=54561231&amp;newsitemid=20260629700344&amp;lan=en-US&amp;anchor=Enveric+Biosciences&amp;index=1&amp;md5=7a69c7ca817d48d6a9aedab8d0cc4e94" shape="rect">Enveric Biosciences</a> (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced its participation in the B. Riley Securities Mind, Muscle &amp; Vision Summit, being held on July 16, 2026, in Boston, MA. Joseph Tucker, Ph.D., CEO of Enveric, will participate in a Neuropsychiatry Fireside Chat to discuss current trends within the neuropsychiatry sector and the outlook for mental health drug development. </p><p> <b>Event Details:</b> </p><table cellspacing="0" class="bwtablemarginb bwblockalignl bwwidth100"> <tr> <td class="bwvertalignt bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwwidth18 bwpadl1" rowspan="1" colspan="1"><p class="bwcellpmargin"> <b>Event:</b> </p> </td> <td class="bwvertalignt http://www.streetinsider.com/Business+Wire/Enveric+Biosciences+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26702308.html Mon, 29 Jun 2026 08:00:00 -0400 A.50202486 ENVB O.05138206 O.53171475 http://www.streetinsider.com/Business+Wire/Enveric+Biosciences+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26702308.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.enveric.com&amp;esheet=54561231&amp;newsitemid=20260629700344&amp;lan=en-US&amp;anchor=Enveric+Biosciences&amp;index=1&amp;md5=7a69c7ca817d48d6a9aedab8d0cc4e94" shape="rect">Enveric Biosciences</a> (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced its participation in the B. Riley Securities Mind, Muscle &amp; Vision Summit, being held on July 16, 2026, in Boston, MA. Joseph Tucker, Ph.D., CEO of Enveric, will participate in a Neuropsychiatry Fireside Chat to discuss current trends within the neuropsychiatry sector and the outlook for mental health drug development. </p><p> <b>Event Details:</b> </p><table cellspacing="0" class="bwtablemarginb bwblockalignl bwwidth100"> <tr> <td class="bwvertalignt bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwwidth18 bwpadl1" rowspan="1" colspan="1"><p class="bwcellpmargin"> <b>Event:</b> </p> </td> <td class="bwvertalignt http://www.streetinsider.com/Business+Wire/Enveric+Biosciences+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26702308.html Mon, 29 Jun 2026 08:00:00 -0400 A.50202486 ENVB O.05138206 O.53171475 http://www.streetinsider.com/Business+Wire/Enveric+Biosciences+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26702308.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.enveric.com&amp;esheet=54561231&amp;newsitemid=20260629700344&amp;lan=en-US&amp;anchor=Enveric+Biosciences&amp;index=1&amp;md5=7a69c7ca817d48d6a9aedab8d0cc4e94" shape="rect">Enveric Biosciences</a> (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced its participation in the B. Riley Securities Mind, Muscle &amp; Vision Summit, being held on July 16, 2026, in Boston, MA. Joseph Tucker, Ph.D., CEO of Enveric, will participate in a Neuropsychiatry Fireside Chat to discuss current trends within the neuropsychiatry sector and the outlook for mental health drug development. </p><p> <b>Event Details:</b> </p><table cellspacing="0" class="bwtablemarginb bwblockalignl bwwidth100"> <tr> <td class="bwvertalignt bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwwidth18 bwpadl1" rowspan="1" colspan="1"><p class="bwcellpmargin"> <b>Event:</b> </p> </td> <td class="bwvertalignt http://www.streetinsider.com/Business+Wire/Enveric+Biosciences+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26702308.html Mon, 29 Jun 2026 08:00:00 -0400 A.50202486 ENVB O.05138206 O.53171475 http://www.streetinsider.com/Business+Wire/Enveric+Biosciences+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26702308.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.enveric.com&amp;esheet=54561231&amp;newsitemid=20260629700344&amp;lan=en-US&amp;anchor=Enveric+Biosciences&amp;index=1&amp;md5=7a69c7ca817d48d6a9aedab8d0cc4e94" shape="rect">Enveric Biosciences</a> (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced its participation in the B. Riley Securities Mind, Muscle &amp; Vision Summit, being held on July 16, 2026, in Boston, MA. Joseph Tucker, Ph.D., CEO of Enveric, will participate in a Neuropsychiatry Fireside Chat to discuss current trends within the neuropsychiatry sector and the outlook for mental health drug development. </p><p> <b>Event Details:</b> </p><table cellspacing="0" class="bwtablemarginb bwblockalignl bwwidth100"> <tr> <td class="bwvertalignt bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwwidth18 bwpadl1" rowspan="1" colspan="1"><p class="bwcellpmargin"> <b>Event:</b> </p> </td> <td class="bwvertalignt http://www.streetinsider.com/Business+Wire/Enveric+Biosciences+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26702308.html Mon, 29 Jun 2026 08:00:00 -0400 A.50202486 ENVB O.05138206 O.53171475 http://www.streetinsider.com/Press+Releases/Enveric+Biosciences+Announces+Participation+in+2026+BIO+International+Convention/26651827.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <b>Enveric Biosciences (NASDAQ: ENVB) </b>(“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that the company is participating in the BIO International Convention being held June 22-25, 2026, in San Diego, California. </p><p> “We are arriving at BIO with strong operational momentum, driven by the recently announced positive preclinical phototoxicity results and the initiation of IND-enabling GLP genotoxicity studies for EB-003,” said Joseph Tucker, Ph.D., CEO of Enveric Biosciences. “This milestone moves us steadily toward IND submission and Phase 1 clinical entry. We are looking http://www.streetinsider.com/Press+Releases/Enveric+Biosciences+Announces+Participation+in+2026+BIO+International+Convention/26651827.html Tue, 16 Jun 2026 09:28:00 -0400 ENVB O.05138206 http://www.streetinsider.com/Press+Releases/Enveric+Biosciences+Announces+Participation+in+2026+BIO+International+Convention/26651827.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <b>Enveric Biosciences (NASDAQ: ENVB) </b>(“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that the company is participating in the BIO International Convention being held June 22-25, 2026, in San Diego, California. </p><p> “We are arriving at BIO with strong operational momentum, driven by the recently announced positive preclinical phototoxicity results and the initiation of IND-enabling GLP genotoxicity studies for EB-003,” said Joseph Tucker, Ph.D., CEO of Enveric Biosciences. “This milestone moves us steadily toward IND submission and Phase 1 clinical entry. We are looking http://www.streetinsider.com/Press+Releases/Enveric+Biosciences+Announces+Participation+in+2026+BIO+International+Convention/26651827.html Tue, 16 Jun 2026 09:28:00 -0400 ENVB O.05138206 http://www.streetinsider.com/Business+Wire/Enveric+Biosciences+Announces+Participation+in+2026+BIO+International+Convention/26651827.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <b>Enveric Biosciences (NASDAQ: ENVB) </b>(“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that the company is participating in the BIO International Convention being held June 22-25, 2026, in San Diego, California. </p><p> “We are arriving at BIO with strong operational momentum, driven by the recently announced positive preclinical phototoxicity results and the initiation of IND-enabling GLP genotoxicity studies for EB-003,” said Joseph Tucker, Ph.D., CEO of Enveric Biosciences. “This milestone moves us steadily toward IND submission and Phase 1 clinical entry. We are looking http://www.streetinsider.com/Business+Wire/Enveric+Biosciences+Announces+Participation+in+2026+BIO+International+Convention/26651827.html Tue, 16 Jun 2026 09:28:00 -0400 ENVB O.05138206 http://www.streetinsider.com/Business+Wire/Enveric+Biosciences+Announces+Participation+in+2026+BIO+International+Convention/26651827.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <b>Enveric Biosciences (NASDAQ: ENVB) </b>(“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that the company is participating in the BIO International Convention being held June 22-25, 2026, in San Diego, California. </p><p> “We are arriving at BIO with strong operational momentum, driven by the recently announced positive preclinical phototoxicity results and the initiation of IND-enabling GLP genotoxicity studies for EB-003,” said Joseph Tucker, Ph.D., CEO of Enveric Biosciences. “This milestone moves us steadily toward IND submission and Phase 1 clinical entry. We are looking http://www.streetinsider.com/Business+Wire/Enveric+Biosciences+Announces+Participation+in+2026+BIO+International+Convention/26651827.html Tue, 16 Jun 2026 09:28:00 -0400 ENVB O.05138206 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Enveric+Biosciences%2C++++++For%3A+Jun+09/26624795.html si-local-file:///var/storage/secattach/20260609/26624795.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Enveric+Biosciences%2C++++++For%3A+Jun+09/26624795.html Tue, 09 Jun 2026 17:17:00 -0400 ENVB O.05138206 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Enveric+Biosciences%2C++++++For%3A+Jun+09/26624795.html si-local-file:///var/storage/secattach/20260609/26624795.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Enveric+Biosciences%2C++++++For%3A+Jun+09/26624795.html Tue, 09 Jun 2026 17:17:00 -0400 ENVB O.05138206 http://www.streetinsider.com/SEC+Filings/Form++424B5++++++Enveric+Biosciences%2C+++++++++++++++++/26624777.html si-local-file:///var/storage/secattach/20260609/26624777.html http://www.streetinsider.com/SEC+Filings/Form++424B5++++++Enveric+Biosciences%2C+++++++++++++++++/26624777.html Tue, 09 Jun 2026 17:15:00 -0400 ENVB O.05138206 http://www.streetinsider.com/SEC+Filings/Form++424B5++++++Enveric+Biosciences%2C+++++++++++++++++/26624777.html si-local-file:///var/storage/secattach/20260609/26624777.html http://www.streetinsider.com/SEC+Filings/Form++424B5++++++Enveric+Biosciences%2C+++++++++++++++++/26624777.html Tue, 09 Jun 2026 17:15:00 -0400 ENVB O.05138206 http://www.streetinsider.com/Press+Releases/Enveric+Biosciences+to+Participate+in+the+UBS+3rd+Virtual+CNS+Day/26620474.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <b>Enveric Biosciences (NASDAQ: ENVB) </b>(“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that the company is participating in the UBS 3rd Virtual CNS Day being held on June 15, 2026. </p><p> During the virtual event, members of Enveric’s management team will conduct one-on-one meetings with registered investors to discuss the company’s business and clinical development strategy, recent corporate achievements, and anticipated milestones. </p><p> <b>About Enveric Biosciences</b> </p><p> Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company focused on developing next-generation, small-molecule neuroplastogenic therapeutics that address unmet needs in psychiatric http://www.streetinsider.com/Press+Releases/Enveric+Biosciences+to+Participate+in+the+UBS+3rd+Virtual+CNS+Day/26620474.html Tue, 09 Jun 2026 08:00:00 -0400 ENVB O.05138206 http://www.streetinsider.com/Press+Releases/Enveric+Biosciences+to+Participate+in+the+UBS+3rd+Virtual+CNS+Day/26620474.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <b>Enveric Biosciences (NASDAQ: ENVB) </b>(“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that the company is participating in the UBS 3rd Virtual CNS Day being held on June 15, 2026. </p><p> During the virtual event, members of Enveric’s management team will conduct one-on-one meetings with registered investors to discuss the company’s business and clinical development strategy, recent corporate achievements, and anticipated milestones. </p><p> <b>About Enveric Biosciences</b> </p><p> Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company focused on developing next-generation, small-molecule neuroplastogenic therapeutics that address unmet needs in psychiatric http://www.streetinsider.com/Press+Releases/Enveric+Biosciences+to+Participate+in+the+UBS+3rd+Virtual+CNS+Day/26620474.html Tue, 09 Jun 2026 08:00:00 -0400 ENVB O.05138206 http://www.streetinsider.com/Business+Wire/Enveric+Biosciences+to+Participate+in+the+UBS+3rd+Virtual+CNS+Day/26620474.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <b>Enveric Biosciences (NASDAQ: ENVB) </b>(“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that the company is participating in the UBS 3rd Virtual CNS Day being held on June 15, 2026. </p><p> During the virtual event, members of Enveric’s management team will conduct one-on-one meetings with registered investors to discuss the company’s business and clinical development strategy, recent corporate achievements, and anticipated milestones. </p><p> <b>About Enveric Biosciences</b> </p><p> Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company focused on developing next-generation, small-molecule neuroplastogenic therapeutics that address unmet needs in psychiatric http://www.streetinsider.com/Business+Wire/Enveric+Biosciences+to+Participate+in+the+UBS+3rd+Virtual+CNS+Day/26620474.html Tue, 09 Jun 2026 08:00:00 -0400 ENVB O.05138206 http://www.streetinsider.com/Business+Wire/Enveric+Biosciences+to+Participate+in+the+UBS+3rd+Virtual+CNS+Day/26620474.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <b>Enveric Biosciences (NASDAQ: ENVB) </b>(“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that the company is participating in the UBS 3rd Virtual CNS Day being held on June 15, 2026. </p><p> During the virtual event, members of Enveric’s management team will conduct one-on-one meetings with registered investors to discuss the company’s business and clinical development strategy, recent corporate achievements, and anticipated milestones. </p><p> <b>About Enveric Biosciences</b> </p><p> Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company focused on developing next-generation, small-molecule neuroplastogenic therapeutics that address unmet needs in psychiatric http://www.streetinsider.com/Business+Wire/Enveric+Biosciences+to+Participate+in+the+UBS+3rd+Virtual+CNS+Day/26620474.html Tue, 09 Jun 2026 08:00:00 -0400 ENVB O.05138206 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Enveric+Biosciences%2C++++++For%3A+Jun+08/26619550.html si-local-file:///var/storage/secattach/20260609/26619550.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Enveric+Biosciences%2C++++++For%3A+Jun+08/26619550.html Tue, 09 Jun 2026 06:00:00 -0400 ENVB O.05138206 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Enveric+Biosciences%2C++++++For%3A+Jun+08/26619550.html si-local-file:///var/storage/secattach/20260609/26619550.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Enveric+Biosciences%2C++++++For%3A+Jun+08/26619550.html Tue, 09 Jun 2026 06:00:00 -0400 ENVB O.05138206 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Enveric+Biosciences%2C++++++For%3A+Jun+01++Filed+by%3A+Coveney+Kevin+Michael/26599596.html si-local-file:///var/storage/secattach/20260603/26599596.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Enveric+Biosciences%2C++++++For%3A+Jun+01++Filed+by%3A+Coveney+Kevin+Michael/26599596.html Wed, 03 Jun 2026 16:35:00 -0400 ENVB O.05138206 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Enveric+Biosciences%2C++++++For%3A+Jun+01++Filed+by%3A+Coveney+Kevin+Michael/26599596.html si-local-file:///var/storage/secattach/20260603/26599596.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Enveric+Biosciences%2C++++++For%3A+Jun+01++Filed+by%3A+Coveney+Kevin+Michael/26599596.html Wed, 03 Jun 2026 16:35:00 -0400 ENVB O.05138206 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Enveric+Biosciences%2C++++++For%3A+Jun+01++Filed+by%3A+Tucker+Joseph+Edward/26599550.html si-local-file:///var/storage/secattach/20260603/26599550.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Enveric+Biosciences%2C++++++For%3A+Jun+01++Filed+by%3A+Tucker+Joseph+Edward/26599550.html Wed, 03 Jun 2026 16:33:00 -0400 ENVB O.05138206